Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Autores da FMUP
Participantes de fora da FMUP
- Dhingra N.K.
- Anker S.D.
- Januzzi J.L.
- Lam C.S.P.
- Peil B.
- Nordaby M.
- Pocock S.J.
- Packer M.
- Anker S.
- Butler J.
- Filippatos G.
- Pocock S.
- Zannad F.
- Brueckmann M.
- George J.
- Jamal W.
- Welty F.K.
- Palmer M.
- Clayton T.
- Parhofer K.G.
- Pedersen T.R.
- Greenberg B.
- Konstam M.A.
- Lees K.R.
- Carson P.
- Doehner W.
- Miller A.
- Haas M.
- Pehrson S.
- Komajda M.
- Anand I.
- Teerlink J.
- Rabinstein A.
- Steiner T.
- Kamel H.
- Tsivgoulis G.
- Lewis J.
- Freston J.
- Kaplowitz N.
- Mann J.
- Petrie J.
- Perrone S.
- Nicholls S.
- Janssens S.
- Bocchi E.
- Giannetti N.
- Verma S.
- Zhang J.
- Spinar J.
- Seronde M.F.
- Boehm M.
- Merkely B.
- Chopra V.
- Senni M.
- Taddi S.
- Tsutsui H.
- Choi D.J.
- Chuquiure E.
- La Rocca H.P.B.
- Ponikowski P.
- Juanatey J.R.G.
- Squire I.
- Januzzi J.
- Pina I.
- Bernstein R.
- Cheung A.
- Green J.
- Kaul S.
- Lam C.
- Lip G.
- Marx N.
- McCullough P.
- Mehta C.
- Rosenstock J.
- Sattar N.
- Scirica B.
- Shah S.
- Wanner C.
- Aizenberg D.
- Cartasegna L.
- Colombo Berra F.
- Colombo H.
- Fernandez Moutin M.
- Glenny J.
- Alvarez Lorio C.
- Anauch D.
- Campos R.
- Facta A.
- Fernandez A.
- Ahuad Guerrero R.
- Lobo Márquez L.
Unidades de investigação
Abstract
Filiações
Filiações não disponíveis
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Dhingra NK,Anker SD,Januzzi JL,Lam CSP,Peil B,Nordaby M,Pocock SJ,Packer M,Anker S,Butler J,Filippatos G,Pocock S,Zannad F,Ferreira JP,Brueckmann M,George J,Jamal W,Welty FK,Palmer M,Clayton T,Parhofer KG,Pedersen TR,Greenberg B,Konstam MA,Lees KR,Carson P,Doehner W,Miller A,Haas M,Pehrson S,Komajda M,Anand I,Teerlink J,Rabinstein A,Steiner T,Kamel H,Tsivgoulis G,Lewis J,Freston J,Kaplowitz N,Mann J,Petrie J,Perrone S,Nicholls S,Janssens S,Bocchi E,Giannetti N,Verma S,Zhang J,Spinar J,Seronde MF,Boehm M,Merkely B,Chopra V,Senni M,Taddi S,Tsutsui H,Choi DJ,Chuquiure E,La Rocca HPB,Ponikowski P,Juanatey JRG,Squire I,Januzzi J,Pina I,Bernstein R,Cheung A,Green J,Kaul S,Lam C,Lip G,Marx N,McCullough P,Mehta C,Rosenstock J,Sattar N,Scirica B,Shah S,Wanner C,Aizenberg D,Cartasegna L,Colombo F,Colombo H,Fernandez M,Glenny J,Alvarez C,Anauch D,Campos R,Facta A,Fernandez A,Ahuad R,Lobo L. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022. 10. (1):p. 35-45. IF:44,500. (1).